US20150065472A1 - Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy - Google Patents
Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy Download PDFInfo
- Publication number
- US20150065472A1 US20150065472A1 US14/396,736 US201314396736A US2015065472A1 US 20150065472 A1 US20150065472 A1 US 20150065472A1 US 201314396736 A US201314396736 A US 201314396736A US 2015065472 A1 US2015065472 A1 US 2015065472A1
- Authority
- US
- United States
- Prior art keywords
- spirox
- methyl
- methylene
- intrauterine
- contraception
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CKSCPQVTRJRMNK-ZBAXIGARSA-N C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@H]5CCC(=O)C=C5CC4)CC[C@@]31CC)CCO2 Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@H]5CCC(=O)C=C5CC4)CC[C@@]31CC)CCO2 CKSCPQVTRJRMNK-ZBAXIGARSA-N 0.000 title claims description 19
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims description 17
- 208000007106 menorrhagia Diseases 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 14
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 28
- 239000004480 active ingredient Substances 0.000 description 21
- 230000009885 systemic effect Effects 0.000 description 17
- 239000012528 membrane Substances 0.000 description 15
- 229960004400 levonorgestrel Drugs 0.000 description 14
- 239000000583 progesterone congener Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229940110234 mirena Drugs 0.000 description 13
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 239000003433 contraceptive agent Substances 0.000 description 9
- 230000002254 contraceptive effect Effects 0.000 description 9
- 239000004205 dimethyl polysiloxane Substances 0.000 description 9
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229940040129 luteinizing hormone Drugs 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 5
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 102000046818 human AR Human genes 0.000 description 5
- -1 polydimethylsiloxane Polymers 0.000 description 5
- 0 [6*][C@@H]1C2=CC(=O)CCC2C2CC[C@@]3(CC)C(C2[C@@H]1[7*])[C@@H]1C[C@@H]1[C@@]31CCCO1 Chemical compound [6*][C@@H]1C2=CC(=O)CCC2C2CC[C@@]3(CC)C(C2[C@@H]1[7*])[C@@H]1C[C@@H]1[C@@]31CCCO1 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 3
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 230000003152 gestagenic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004073 vulcanization Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- AKKBZJOOJOLPTM-DHSLEBKISA-N CC[C@](CC1)(C(C2[C@@H]3[C@H]2C)C(C2[C@@H]4C2)C1C(CC1)C4=CC1=O)[C@@]31OCCC1 Chemical compound CC[C@](CC1)(C(C2[C@@H]3[C@H]2C)C(C2[C@@H]4C2)C1C(CC1)C4=CC1=O)[C@@]31OCCC1 AKKBZJOOJOLPTM-DHSLEBKISA-N 0.000 description 1
- WJFZIXHVLPMHIH-HXZDQDKDSA-N CC[C@]12CCC3C4CCC(=O)C=C4CCC3C1[C@@H]1C[C@@H]1[C@@]21CCCO1.CC[C@]12CCC3C4CCC(=O)C=C4[C@H]4C[C@H]4C3C1[C@@H]1C[C@@H]1[C@@]21CCCO1 Chemical compound CC[C@]12CCC3C4CCC(=O)C=C4CCC3C1[C@@H]1C[C@@H]1[C@@]21CCCO1.CC[C@]12CCC3C4CCC(=O)C=C4[C@H]4C[C@H]4C3C1[C@@H]1C[C@@H]1[C@@]21CCCO1 WJFZIXHVLPMHIH-HXZDQDKDSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 230000016117 decidualization Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- the amounts of active ingredient (A) or (B) released were determined by means of reversed-phase liquid chromatography with UV detection in a 1% strength 2-hydroxypropyl- ⁇ -cyclodextrin (2-HPBCD) solution.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012206652 | 2012-04-23 | ||
| DE102012206652.7 | 2012-04-23 | ||
| PCT/EP2013/058220 WO2013160213A1 (de) | 2012-04-23 | 2013-04-19 | INTRAUTERINE ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN, INTRAUTERINE SYSTEME ENTHALTEND 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE, SOWIE DEREN VERWENDUNG IN DER KONTRAZEPTION UND GYNÄKOLOGISCHEN THERAPIE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20150065472A1 true US20150065472A1 (en) | 2015-03-05 |
Family
ID=48142002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/396,736 Abandoned US20150065472A1 (en) | 2012-04-23 | 2013-04-19 | Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy |
Country Status (28)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015055789A1 (en) * | 2013-10-17 | 2015-04-23 | Bayer Pharma Aktiengesellschaft | INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143359A1 (en) * | 2003-07-16 | 2005-06-30 | Bell Robert G. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| US7846917B2 (en) * | 2006-06-29 | 2010-12-07 | Bayer Schering Pharma Ag | 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same |
| US20110003779A1 (en) * | 2007-12-29 | 2011-01-06 | Ulrich Klar | 15, 16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative , use thereof, and medicament containing said derivative |
| US20110146693A1 (en) * | 2008-07-03 | 2011-06-23 | Bernd Duesterberg | Intrauterine delivery system for contraception |
| WO2012063262A2 (en) * | 2010-11-08 | 2012-05-18 | Hll Lifecare Limited | A novel intrauterine device with controlled copper release |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH30867A (en) | 1992-07-31 | 1997-12-09 | Leiras Oy | Method and equipment for installing a medicine capsule on a support. |
| FI90627C (fi) | 1992-07-31 | 1994-03-10 | Leiras Oy | Laitteisto lääkeainesauvan varustamiseksi vaipalla |
| FI107339B (fi) | 1998-06-30 | 2001-07-13 | Leiras Oy | Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi |
| US6056976A (en) | 1998-11-12 | 2000-05-02 | Leiras Oy | Elastomer, its preparation and use |
| SI1611892T1 (sl) * | 2000-01-18 | 2010-01-29 | Bayer Schering Pharma Ag | Farmacevtski sestavki, ki obsegajo drospirenon |
| DE102007011105A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| DE102007063495A1 (de) * | 2007-12-29 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel |
-
2013
- 2013-04-11 TW TW102112904A patent/TW201350122A/zh unknown
- 2013-04-19 HK HK15105985.9A patent/HK1205000A1/xx unknown
- 2013-04-19 EA EA201491922A patent/EA201491922A1/ru unknown
- 2013-04-19 KR KR1020147029292A patent/KR20150004807A/ko not_active Withdrawn
- 2013-04-19 JP JP2015507482A patent/JP2015514791A/ja active Pending
- 2013-04-19 US US14/396,736 patent/US20150065472A1/en not_active Abandoned
- 2013-04-19 SG SG11201406582XA patent/SG11201406582XA/en unknown
- 2013-04-19 AU AU2013254840A patent/AU2013254840A1/en not_active Abandoned
- 2013-04-19 PE PE2014001786A patent/PE20142438A1/es not_active Application Discontinuation
- 2013-04-19 WO PCT/EP2013/058220 patent/WO2013160213A1/de active Application Filing
- 2013-04-19 EP EP13717289.6A patent/EP2841074A1/de not_active Withdrawn
- 2013-04-19 IN IN7839DEN2014 patent/IN2014DN07839A/en unknown
- 2013-04-19 MX MX2014012849A patent/MX2014012849A/es unknown
- 2013-04-19 CA CA2871003A patent/CA2871003A1/en not_active Abandoned
- 2013-04-19 BR BR112014026193A patent/BR112014026193A2/pt not_active Application Discontinuation
- 2013-04-19 CN CN201380021453.6A patent/CN104254333A/zh active Pending
- 2013-04-23 AR ARP130101341A patent/AR090799A1/es unknown
- 2013-04-23 UY UY0001034758A patent/UY34758A/es not_active Application Discontinuation
-
2014
- 2014-10-19 IL IL235095A patent/IL235095A0/en unknown
- 2014-10-21 CL CL2014002836A patent/CL2014002836A1/es unknown
- 2014-10-21 MA MA37444A patent/MA37444A1/fr unknown
- 2014-10-22 TN TN2014000444A patent/TN2014000444A1/fr unknown
- 2014-10-22 PH PH12014502372A patent/PH12014502372A1/en unknown
- 2014-10-23 CO CO14235159A patent/CO7111255A2/es unknown
- 2014-10-23 DO DO2014000241A patent/DOP2014000241A/es unknown
- 2014-10-23 CU CU2014000121A patent/CU20140121A7/es unknown
- 2014-10-23 CR CR20140490A patent/CR20140490A/es unknown
- 2014-10-24 EC ECIEPI201424250A patent/ECSP14024250A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143359A1 (en) * | 2003-07-16 | 2005-06-30 | Bell Robert G. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
| US7846917B2 (en) * | 2006-06-29 | 2010-12-07 | Bayer Schering Pharma Ag | 18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same |
| US20110003779A1 (en) * | 2007-12-29 | 2011-01-06 | Ulrich Klar | 15, 16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative , use thereof, and medicament containing said derivative |
| US8623850B2 (en) * | 2007-12-29 | 2014-01-07 | Bayer Intellectual Property Gmbh | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative |
| US20110146693A1 (en) * | 2008-07-03 | 2011-06-23 | Bernd Duesterberg | Intrauterine delivery system for contraception |
| WO2012063262A2 (en) * | 2010-11-08 | 2012-05-18 | Hll Lifecare Limited | A novel intrauterine device with controlled copper release |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150004807A (ko) | 2015-01-13 |
| JP2015514791A (ja) | 2015-05-21 |
| ECSP14024250A (es) | 2015-12-31 |
| CR20140490A (es) | 2014-11-17 |
| WO2013160213A1 (de) | 2013-10-31 |
| AU2013254840A1 (en) | 2014-11-06 |
| DOP2014000241A (es) | 2014-12-31 |
| SG11201406582XA (en) | 2014-11-27 |
| EP2841074A1 (de) | 2015-03-04 |
| IN2014DN07839A (enrdf_load_stackoverflow) | 2015-04-24 |
| MX2014012849A (es) | 2015-02-05 |
| PE20142438A1 (es) | 2015-02-01 |
| MA37444A1 (fr) | 2016-11-30 |
| TW201350122A (zh) | 2013-12-16 |
| CO7111255A2 (es) | 2014-11-10 |
| IL235095A0 (en) | 2014-12-31 |
| AR090799A1 (es) | 2014-12-10 |
| CL2014002836A1 (es) | 2015-03-13 |
| HK1205000A1 (en) | 2015-12-11 |
| PH12014502372A1 (en) | 2015-01-26 |
| CA2871003A1 (en) | 2013-10-31 |
| CN104254333A (zh) | 2014-12-31 |
| EA201491922A1 (ru) | 2015-04-30 |
| BR112014026193A2 (pt) | 2017-06-27 |
| TN2014000444A1 (en) | 2016-03-30 |
| CU20140121A7 (es) | 2014-12-26 |
| UY34758A (es) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10532025B2 (en) | Intrauterine delivery system for contraception | |
| AU2011234587B2 (en) | Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis | |
| US20160262923A1 (en) | Intrauterine delivery system | |
| JP2025510716A (ja) | シリコーン材料、シリコーンチューブ、インプラント、医薬組成物、薬物放出量の測定方法 | |
| US20150065472A1 (en) | Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy | |
| US20150119372A1 (en) | Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders | |
| TW201529058A (zh) | 子宮內遞送系統 | |
| HK1221634A1 (zh) | 子宫内递送系统 | |
| HK1157208A (en) | An intrauterine delivery system for contraception | |
| HK1197641A (en) | An intrauterine delivery system for contraception |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHMEES, NORBERT, DR.;ROESE, LARS, DR.;VALO, TUULA;AND OTHERS;SIGNING DATES FROM 20140811 TO 20140904;REEL/FRAME:034700/0339 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |